Evidence map›Paper›PMID 34963481›Full record

ArticleInfectious diseases of poverty2021

The optimal vaccination strategy to control COVID-19: a modeling study in Wuhan City, China.

Ze-Yu Zhao, Yan Niu, Li Luo, Qing-Qing Hu, Tian-Long Yang, Mei-Jie Chu, Qiu-Ping Chen, Zhao Lei, Jia Rui, Cheng-Long Song and 17 more

Abstract read
In one paragraph

Article in Infectious diseases of poverty, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Ze-Yu Zhao *State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, 4221-117 South Xiang'an Road, Xiang'an District, Xiamen, 361102, Fujian, People's Republic of China.
Yan Niu *Chinese Center for Disease Control and Prevention, Beijing, People's Republic of China.
Li Luo *State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, 4221-117 South Xiang'an Road, Xiang'an District, Xiamen, 361102, Fujian, People's Republic of China.
Qing-Qing HuDivision of Public Health, School of Medicine, University of Utah, Utah, USA.
Tian-Long YangState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, 4221-117 South Xiang'an Road, Xiang'an District, Xiamen, 361102, Fujian, People's Republic of China.
Mei-Jie ChuState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, 4221-117 South Xiang'an Road, Xiang'an District, Xiamen, 361102, Fujian, People's Republic of China.
Qiu-Ping ChenCirad, UMR 17, Intertryp, Université de Montpellier, Montpellier, France.
Zhao LeiState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, 4221-117 South Xiang'an Road, Xiang'an District, Xiamen, 361102, Fujian, People's Republic of China.
Jia RuiState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, 4221-117 South Xiang'an Road, Xiang'an District, Xiamen, 361102, Fujian, People's Republic of China.
Cheng-Long SongDepartment of Data Science, College of Natural Sciences, Colorado State University, Fort Collins, CO, USA.
Sheng-Nan LinState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, 4221-117 South Xiang'an Road, Xiang'an District, Xiamen, 361102, Fujian, People's Republic of China.
Yao WangState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, 4221-117 South Xiang'an Road, Xiang'an District, Xiamen, 361102, Fujian, People's Republic of China.
Jing-Wen XuState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, 4221-117 South Xiang'an Road, Xiang'an District, Xiamen, 361102, Fujian, People's Republic of China.
Yuan-Zhao ZhuState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, 4221-117 South Xiang'an Road, Xiang'an District, Xiamen, 361102, Fujian, People's Republic of China.
Xing-Chun LiuState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, 4221-117 South Xiang'an Road, Xiang'an District, Xiamen, 361102, Fujian, People's Republic of China.
Meng YangState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, 4221-117 South Xiang'an Road, Xiang'an District, Xiamen, 361102, Fujian, People's Republic of China.
Jie-Feng HuangState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, 4221-117 South Xiang'an Road, Xiang'an District, Xiamen, 361102, Fujian, People's Republic of China.
Wei-Kang LiuState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, 4221-117 South Xiang'an Road, Xiang'an District, Xiamen, 361102, Fujian, People's Republic of China.
Bin DengState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, 4221-117 South Xiang'an Road, Xiang'an District, Xiamen, 361102, Fujian, People's Republic of China.
Chan LiuState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, 4221-117 South Xiang'an Road, Xiang'an District, Xiamen, 361102, Fujian, People's Republic of China.
Zhuo-Yang LiState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, 4221-117 South Xiang'an Road, Xiang'an District, Xiamen, 361102, Fujian, People's Republic of China.
Pei-Hua LiState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, 4221-117 South Xiang'an Road, Xiang'an District, Xiamen, 361102, Fujian, People's Republic of China.
Yan-Hua SuState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, 4221-117 South Xiang'an Road, Xiang'an District, Xiamen, 361102, Fujian, People's Republic of China.
Ben-Hua ZhaoState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, 4221-117 South Xiang'an Road, Xiang'an District, Xiamen, 361102, Fujian, People's Republic of China.
Wen-Long HuangFujian Provincial Center for Disease Control and Prevention, 76 Jintai Road, Gulou District, Fuzhou, Fujian, People's Republic of China. 497528061@qq.com.
Roger FrutosCirad, UMR 17, Intertryp, Université de Montpellier, Montpellier, France. frutossmt@gmail.com.
Tian-Mu ChenState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, 4221-117 South Xiang'an Road, Xiang'an District, Xiamen, 361102, Fujian, People's Republic of China. 13698665@qq.com.ORCID http://orcid.org/0000-0003-0710-5086

Funding

Gates Foundation INV-005834NHC Key Laboratory of Echinococcosis Prevention and Control 2020WZK2001the Science and Technology Program of Fujian Province 2020Y0002
6 · The paper itself

Abstract

backgroundReaching optimal vaccination rates is an essential public health strategy to control the coronavirus disease 2019 (COVID-19) pandemic. This study aimed to simulate the optimal vaccination strategy to control the disease by developing an age-specific model based on the current transmission patterns of COVID-19 in Wuhan City, China.

methodsWe collected two indicators of COVID-19, including illness onset data and age of confirmed case in Wuhan City, from December 2, 2019, to March 16, 2020. The reported cases were divided into four age groups: group 1, ≤ 14 years old; group 2, 15 to 44 years old; group 3, 44 to 64 years old; and group 4, ≥ 65 years old. An age-specific susceptible-exposed-symptomatic-asymptomatic-recovered/removed model was developed to estimate the transmissibility and simulate the optimal vaccination strategy. The effective reproduction number (R

resultsA total of 47 722 new cases were reported in Wuhan City from December 2, 2019, to March 16, 2020. Before the travel ban of Wuhan City, the highest transmissibility was observed among age group 2 (R

conclusionsApproximately 85% of the total population (nearly 1.2 billion people) should be vaccinated to build an immune barrier in China to safely consider removing border restrictions. Based on these results, we concluded that 90% of adults aged 15-64 years should first be vaccinated to prevent transmission in China.

Indexed as

COVID-19AdolescentAdultAgedChinaCitiesHumansMiddle AgedSARS-CoV-2VaccinationYoung AdultAge-specific modelEffectivenessSARS-CoV-2TransmissibilityVaccination strategy

Identifiers

PMID34963481
PMCPMC8712277

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.